Cargando…

Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice

AZD1222 (ChAdOx1 nCoV-19) is a COVID-19 vaccine that is not yet licensed for use during pregnancy. To support the inclusion of pregnant and breastfeeding people in AZD1222 clinical studies, a non-clinical developmental and reproductive toxicity study was performed to evaluate its effects on fertilit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stebbings, Richard, Maguire, Shaun, Armour, Gillian, Jones, Christopher, Goodman, Joanne, Maguire, Anna Karin, Tang, Chi Man, Skellett, Vicky, Harris, Jayne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759091/ https://www.ncbi.nlm.nih.gov/pubmed/34324966 http://dx.doi.org/10.1016/j.reprotox.2021.07.010

Ejemplares similares

AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice
por: Stebbings, Richard, et al.
Publicado: (2022)

SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19)
por: Stebbings, Richard, et al.
Publicado: (2022)

S-11-03 Accelerated timelines for non-clinical studies to support COVID-19 vaccine (AZD1222, ChAdOx1-nCov19)
por: Stebbings, R.
Publicado: (2022)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
por: Hillson, Kushalinii, et al.
Publicado: (2021)

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
por: Soboleva, Karina, et al.
Publicado: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
por: Marchevsky, Natalie Gabrielle, et al.
Publicado: (2022)

Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations
por: Laffan, Michael A, et al.
Publicado: (2022)

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients
por: Bhadauria, Dharmendra S., et al.
Publicado: (2022)

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
por: Falsey, Ann R., et al.
Publicado: (2021)

Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)
por: Ho, Jonathan D., et al.
Publicado: (2022)

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Saraceno, Janaína Jamile Ferreira, et al.
Publicado: (2021)

Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Rangsrisaeneepitak, Vimonsri, et al.
Publicado: (2022)

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
por: Benkeser, David, et al.
Publicado: (2023)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
por: Al Bahrani, Salma, et al.
Publicado: (2021)

Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai
por: Shetty, Arusha, et al.
Publicado: (2022)

Acute herpes zoster radiculopathy mimicking cervical radiculopathy after ChAdOx1 nCoV-19/AZD1222 vaccination
por: Dermawan, Andrew, et al.
Publicado: (2022)

Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
por: Cohen, Taylor S., et al.
Publicado: (2022)

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
por: Sobieszczyk, Magdalena E., et al.
Publicado: (2022)

Livedo reticularis following administration of ChAdOx1 nCoV-19 vaccine (AZD1222): a report of two cases
por: Kim, Joong Ho, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
por: Kaplonek, Paulina, et al.
Publicado: (2023)

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
por: Watanabe, Yasunori, et al.
Publicado: (2021)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
por: Clemens, Sue Ann Costa, et al.
Publicado: (2021)

Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle
por: Choi, Hyunji, et al.
Publicado: (2021)

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
por: Marsh, Glenn A., et al.
Publicado: (2021)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
por: Watanabe, Yasunori, et al.
Publicado: (2021)

Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana
por: Shava, Emily, et al.
Publicado: (2023)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
por: Terpos, Evangelos, et al.
Publicado: (2021)

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
por: Voysey, Merryn, et al.
Publicado: (2023)

Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study
por: Mishra, Sanjeeb K, et al.
Publicado: (2021)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2
por: Lee, Sang Won, et al.
Publicado: (2021)

Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers
por: Lim, Sera, et al.
Publicado: (2022)

LB6. Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19)
por: Sobieszczyk, Magdalena, et al.
Publicado: (2021)

Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases
por: Chen, Yen-Ju, et al.
Publicado: (2022)

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T(H)1 response with a diverse TCR repertoire
por: Swanson, Phillip A., et al.
Publicado: (2021)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population
por: Sirisreetreerux, Supamas, et al.
Publicado: (2023)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
por: Voysey, Merryn, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_860qll9fit3732t7d94ve3mbvm